A clinical trial update dated May 19, 2026 lists a Phase 2 study involving tesamorelin as currently recruiting. The trial, registered as NCT06554717, is titled "Tesamorelin as an Adjunct to Exercise for Improving Physical Function in HIV."
According to the listing, the study is evaluating tesamorelin used alongside an exercise program in people with HIV, with a focus on physical function outcomes. The trial is designated Phase 2 and its status is recorded as recruiting as of the date given.
No results have been posted for this study at this stage, and none should be assumed. The event data does not include findings, enrollment numbers, or completion timelines beyond the current recruiting status.
Tesamorelin is noted here in the context of research use. This update reflects only the trial's current phase and recruitment status as listed on ClinicalTrials.gov under the identifier NCT06554717.
Readers interested in more background on this compound can consult the compound overview for additional context.